Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
(Pembrolizumab + vibostolimab) by Merck for Metastatic Renal Cell Carcinoma: Likelihood of Approval
(Pembrolizumab + vibostolimab) is under clinical development by Merck and currently in Phase II for Metastatic Renal Cell Carcinoma. According...
Data Insights
(Pembrolizumab + vibostolimab) by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
(Pembrolizumab + vibostolimab) is under clinical development by Merck and currently in Phase III for Non-Small Cell Lung Cancer. According...